• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD face a difficult decision regarding whether or not to stop taking ADHD medication during pregnancy and breastfeeding. There aren't many studies on how exposure to ADHD for a long time could affect the foetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological problems like hearing loss or vision, febrile seizures, or IQ impairment. The authors acknowledge that more high-quality studies are required.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medication must weigh the benefits of taking it versus the risks to the fetus. The doctors don't have the information to provide clear recommendations however they can provide information on risks and benefits to aid pregnant women in making an informed decision.

A study published in Molecular Psychiatry found that women who took ADHD medications during early pregnancy did not face an increased risk of fetal heart malformations or major structural birth defects. Researchers used a vast population-based case-control study to determine the prevalence of major structural birth defects in infants born to mothers who took stimulants during early pregnancy and those who had not. Pediatric cardiologists and clinical geneticists looked over the cases to ensure correct case classification and to limit the possibility of bias.

The study of the researchers was not without its limitations. In particular, they were not able to differentiate the effects of the medication from the effects of the underlying disorder. This limitation makes it difficult for researchers to determine if the small associations observed among the groups exposed were due to medication use or if they were affected by the presence of comorbidities. The researchers also did not look at the long-term effects for the offspring.

The study did reveal that babies whose mothers had taken ADHD medication during pregnancy were at a slightly greater risk of being admitted to the neonatal intensive care unit (NICU) than those who whose mothers did not take any medication or stopped their medications before or during pregnancy. This was due to central nervous system disorders. The increased risk of admission was not affected by the stimulant medications used during pregnancy.

Women who took stimulant ADHD medication during pregnancy also had an elevated chance of having a caesarean section or having a child with a low Apgar score (less than 7). These increases did not appear to be affected by the type of medication that was used during pregnancy.

The research suggests that the risk of a small amount with the use of ADHD medications during the early stages of pregnancy could be offset by the greater benefit for both mother and child of continuing treatment for the woman's disorder. Doctors should discuss with their patients about this issue and, if possible, help them improve coping skills which could reduce the impact of her disorder in her daily life and relationships.

Interactions with Medication

Many doctors are confronted with the dilemma of whether to keep treatment or stop it during pregnancy as more women are diagnosed with ADHD. Often, these decisions are made without clear and authoritative evidence regardless, so doctors have to weigh their experience from their own experiences, those of other doctors, and what research suggests on the subject and their best judgment for each patient.

In particular, the issue of potential risks to the baby can be a challenge. Many studies on this topic are based on observational data rather than controlled research and their conclusions are often contradictory. The majority of studies restrict their analysis to live births, which can underestimate the teratogenic impact which Can general practitioners prescribe adhd medication cause terminations or abortions of pregnancy. The study that is discussed in the journal club addresses these limitations, by examining both information on deceased and live births.

The conclusion: While some studies have shown that there is a positive correlation between ADHD medications and the possibility of certain birth defects, others have not found any evidence of a link, and most studies demonstrate a neutral or slight negative effect. Therefore an accurate risk-benefit analysis is required in every instance.

It can be difficult, if not impossible, for women suffering from ADHD to stop taking their medication. In a recent article in the Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can increase depression and feelings of being isolated. A decrease in medication could also impact the ability to drive safely and perform work-related tasks, which are vital aspects of daily life for people with ADHD.

She recommends women who are uncertain about whether to keep or stop medication in light of their pregnancy consider educating family members, friends, and coworkers on the condition, its impact on daily functioning, and the advantages of staying on the current treatment plan. It can also help women feel more confident in her decision. It is important to note that some medications can pass through the placenta so if the patient decides to discontinue her ADHD medication during pregnancy and breastfeeding, she should be aware that the effects of the drug could be transferred to the child.

Birth Defects and Risk of

As the use of ADHD medications to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases there are concerns about what impact the drugs could have on foetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge on this subject. Researchers used two massive datasets to analyze over 4.3 million pregnancy and determine if the use of stimulant medications caused birth defects. Researchers found that while the risk overall is low, first-trimester ADHD medication exposure was associated with slightly higher rates of certain heart defects, such as ventriculoseptal defect.

The authors of the study could not discover any connection between early use of medication and other congenital anomalies like facial deformities or club feet. The results are in line with previous studies that have shown an insignificant, but small increase in the number of cardiac malformations among women who started taking ADHD medication prior to pregnancy. The risk increased in the latter half of pregnancy when a large number of women decided to stop taking their medication.

Women who used ADHD medications in the first trimester of their pregnancies were also more likely to have caesarean section, low Apgar score following delivery, and a baby who required help breathing at birth. The authors of the study were unable to eliminate bias due to selection because they limited the study to women without other medical conditions that could have contributed to the findings.

Researchers hope their research will help doctors when they meet pregnant women. They recommend that, while a discussion of the benefits and risks is important, the decision to stop or maintain medication should be based on each woman's requirements and the severity of her safest adhd medication for adults symptoms.

The authors also advise that, while stopping the medication is an alternative, it is not an option that is recommended due to the high incidence of depression and other mental health issues among women who are pregnant or postpartum. Furthermore, research suggests that women who choose to stop taking their medications are more likely to have a difficult time getting used to life without them after the baby's arrival.

Nursing

It can be a challenge becoming a mother. Women who suffer from ADHD who must work through their symptoms while attending physician appointments, making preparations for the arrival of a child and adapting to new routines in the home may face a lot of challenges. Many women opt to continue taking their ADHD medication during pregnancy.

The majority of stimulant drugs are absorbed through breast milk in low quantities, so the risk for breastfeeding infant is minimal. However, the frequency of exposure to medication by the newborn can vary depending on the dosage, frequency it is administered and the time of the day the medication is administered. Additionally, individual medications enter the infant's system differently through the gastrointestinal tract as well as breast milk, and the effect of this on a newborn is not yet fully known.

Due to the absence of research, some doctors might be tempted to stop taking stimulant medication during the course of pregnancy. It is a difficult decision for the mother, who must weigh the benefits of continuing her medication against the risks to the foetus. As long as there is no more information, doctors should ask all pregnant patients about their experience with ADHD and whether they are planning or taking to take medication during the perinatal period.

Numerous studies have demonstrated that women can continue taking their ADHD medication in a safe manner during pregnancy and while breast-feeding. In response, an increasing number of patients are choosing to do so. They have concluded after consulting with their doctors, that the benefits of continuing their current medication outweigh risk.

It is essential for women with ADHD who are thinking of breastfeeding to seek out a specialist psychiatrist's advice prior to becoming pregnant. They should review their medications with their prescriber and discuss the advantages and disadvantages of continuing treatment, including non-pharmacological strategies. Psychoeducation is also necessary to help pregnant women suffering from ADHD understand the symptoms and the underlying disorder. They should also be educated about treatment options and build coping mechanisms. This should be a multidisciplinary approach with the GP doctors, obstetricians and psychiatrists. Pregnancy counseling should consist of a discussion of a treatment plan for the mother and the child, and monitoring for indicators of deterioration, and, if necessary, adjustments to the medication regime.